# OPTImal Management of Antithrombotic Agents: OPTIMA-5

> **NCT04116931** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Acute Coronary Syndrome (ACS)

## Interventions

- **DRUG:** Switch ticagrelor to clopidogrel

## Key facts

- **NCT ID:** NCT04116931
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-22
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116931, "OPTImal Management of Antithrombotic Agents: OPTIMA-5". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT04116931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*